Published in Pediatr Nephrol on March 12, 2008
Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatr Nephrol (2008) 1.30
Assessment of crystallization risk formulas in pediatric calcium stone-formers. Pediatr Nephrol (2009) 0.81
Urolithiasis--an interdisciplinary diagnostic, therapeutic and secondary preventive challenge. Dtsch Arztebl Int (2015) 0.80
Relevance of the BONN Risk Index for metabolic monitoring of patients with calcium oxalate urolithiasis: a clinical application study of the Urolizer. Urol Res (2009) 0.79
Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies. World J Nephrol (2015) 0.78
Evaluation of pediatric nephrolithiasis. Indian J Urol (2010) 0.75
Spontaneous urinary calcium oxalate crystallization in hypercalciuric children. Pediatr Nephrol (2009) 0.75
Kinetics of calcium oxalate crystal formation in urine. Urolithiasis (2016) 0.75
EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol (1985) 2.71
Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol (2007) 1.86
A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol (1999) 1.53
Urinary excretion of acid mucopolysaccharides in normal children and patients with gargoylism. J Lab Clin Med (1962) 1.44
Kidney stones. Lancet (1998) 1.41
Pediatric urolithiasis. Urol Clin North Am (1997) 1.24
Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab (1985) 1.19
Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas. J Urol (2004) 1.16
Clinical outcome of pediatric stone disease. J Urol (2002) 1.12
Nephrolithiasis in children. Pediatr Nephrol (2005) 1.12
Risk formulas in calcium oxalate urolithiasis. World J Urol (1997) 1.11
A new approach to calculate the risk of calcium oxalate crystallization from unprepared native urine. Urol Res (2000) 1.07
Physiology of acid-base balance: links with kidney stone prevention. Semin Nephrol (2006) 1.05
Metabolic risk factors in pediatric and adult calcium oxalate urinary stone formers: is there any difference? Urol Int (2003) 1.03
Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci (2003) 1.02
Pediatric urolithiasis--evaluation of risk factors in 95 children. Scand J Urol Nephrol (2003) 1.00
Dual role of citrate in mammalian urine. Curr Opin Nephrol Hypertens (2006) 0.97
Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients. J Urol (2002) 0.96
Urinary metabolic evaluations in normal and stone forming children. J Urol (2006) 0.96
Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls? J Urol (2006) 0.94
Normative data on the Bonn Risk Index for calcium oxalate crystallization in healthy children. Pediatr Nephrol (2007) 0.89
Oxalate and its handling in a low stone risk vs a stone-prone population group. World J Urol (2005) 0.85
Comparison of laser-probe and photometric determination of the urinary crystallization risk of calcium oxalate. Clin Chem Lab Med (2002) 0.82
Determination of urinary calcium-oxalate formation risk with BONN-Risk-Index and EQUIL applied to a family. J Chem Inf Comput Sci (2002) 0.82
Levels of urinary inter-alpha-trypsin inhibitor trimer as a function of age and sex-hormone status in males and females not forming stones. BJU Int (2002) 0.78
Renal calculi in children: imaging features that lead to diagnoses: a pictorial essay. Pediatr Radiol (1999) 0.78
Markers of systemic inflammation in children with hyperuricemia. Acta Paediatr (2012) 1.48
Assessment of lithogenic risk in children based on a morning spot urine sample. J Urol (2010) 1.45
Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol (2013) 1.25
KIM-1 and NGAL: new markers of obstructive nephropathy. Pediatr Nephrol (2011) 1.23
Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol (2010) 1.11
Patients' perceptions of GP non-verbal communication: a qualitative study. Br J Gen Pract (2010) 1.07
Hypertension in dialysed children: the prevalence and therapeutic approach in Poland--a nationwide survey. Nephrol Dial Transplant (2005) 0.91
MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol (2006) 0.90
Normative data on the Bonn Risk Index for calcium oxalate crystallization in healthy children. Pediatr Nephrol (2007) 0.89
The patient's view of the acceptability of the primary care in Poland. Int J Qual Health Care (2008) 0.88
Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutations. Eur J Pediatr (2010) 0.86
Involvement of family nurses in home visits during an 8-year period encompassing primary healthcare reforms in Poland. Health Soc Care Community (2008) 0.85
Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. Pediatr Nephrol (2010) 0.81
Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scand J Urol Nephrol (2010) 0.81
Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome. Pediatr Nephrol (2008) 0.81
Evaluation of bladder instability in children with recurrent urinary tract infections. Med Sci Monit (2002) 0.81
Assessment of serum cystatin C in children with congenital solitary kidney. Pediatr Nephrol (2006) 0.81
Little evidence of low bone mass in acute lymphoblastic leukemia survivors. J Clin Densitom (2011) 0.80
Expression of glucocorticoid receptors in mononuclear cells in nephrotic syndrome. Pediatr Nephrol (2003) 0.80
Correspondence between Ca²⁺ and calciuria, citrate level and pH of urine in pediatric urolithiasis. Pediatr Nephrol (2013) 0.80
A potential pathogenic role of oxalate in autism. Eur J Paediatr Neurol (2011) 0.80
Subclinical cardiovascular system changes in obese patients with juvenile idiopathic arthritis. Mediators Inflamm (2013) 0.79
Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response. Pediatr Nephrol (2006) 0.79
Functional bladder capacity and urine osmolality in children with primary monosymptomatic nocturnal enuresis. Scand J Urol Nephrol (2005) 0.79
[Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia]. Pol Merkur Lekarski (2007) 0.79
Comparison of phalangeal ultrasound and dual energy X-ray absorptiometry in healthy male and female adolescents. Ultrasound Med Biol (2005) 0.78
Glucocorticoid receptor and vascular endothelial growth factor in nephrotic syndrome. Acta Paediatr (2006) 0.78
Is plasma symmetric dimethylarginine a suitable marker of renal function in children and adolescents? Scand J Urol Nephrol (2011) 0.78
A need to establish normative data for plasma oxalates. Am J Kidney Dis (2008) 0.78
Reference values of plasma oxalate in children and adolescents. Pediatr Nephrol (2008) 0.78
Body composition and bone mass in survivors of childhood cancer. Pediatr Blood Cancer (2007) 0.78
[Bone mineral density in children before and after completion of cancer treatment]. Pol Merkur Lekarski (2004) 0.77
[Serum and urinary homocysteine in children with steroid-dependent nephrotic syndrome]. Pol Merkur Lekarski (2011) 0.77
[WT1 mutation as a cause of progressive nephropathy in Frasier syndrome--case report]. Pol Merkur Lekarski (2009) 0.77
Is the treatment for childhood solid tumors associated with lower bone mass than that for leukemia and Hodgkin disease? Pediatr Hematol Oncol (2009) 0.76
Does Q223R Polymorphism of Leptin Receptor Influence on Anthropometric Parameters and Bone Density in Childhood Cancer Survivors? Int J Endocrinol (2013) 0.76
[Chronic peritoneal dialysis in infants--preliminary results of the multicenter survey]. Przegl Lek (2006) 0.76
Urinary transforming growth factor beta1 in children and adolescents with congenital solitary kidney. Pediatr Nephrol (2008) 0.76
Laminin and transforming growth factor beta-1 in children with vesicoureteric reflux. Pediatr Nephrol (2008) 0.76
Is symmetric dimethylarginine a sensitive biomarker of subclinical kidney injury in children born with low birth weight? Biomarkers (2014) 0.76
Serum and urine leptin concentration in children with nephrotic syndrome. Pediatr Nephrol (2005) 0.75
High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome. Pediatr Nephrol (2006) 0.75
Expression of glucocorticoid receptors in nephrotic children depending on total prednisone dose. J Pediatr Endocrinol Metab (2005) 0.75
The effects of breastfeeding on serum asymmetric dimethylarginine levels and body composition in children. Breastfeed Med (2014) 0.75
Some remarks on self-reported and measured height and weight in adolescents. J Adolesc Health (2006) 0.75
Serum matrix metalloproteinase-9 levels and severity of symptoms in boys with attention deficit hyperactivity disorder ADHD/hyperkinetic disorder HKD. Eur Child Adolesc Psychiatry (2014) 0.75
Low milk consumption in childhood and fragility fractures. Comment on an article by Monti et al. Ann Nutr Metab (2008) 0.75
Urinary citrate excretion in healthy children depends on age and gender. Pediatr Nephrol (2014) 0.75
Asymmetric and symmetric dimethylarginine in adolescents with hyperuricemia. Dis Markers (2013) 0.75
New insight into the role of patients during medical appointments: a synthesis of three qualitative studies. Patient (2014) 0.75
[Urinary laminin and fibronectin level in children with nephritic syndrome]. Pol Merkur Lekarski (2009) 0.75
[Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in the urine of children with pyelonephritis]. Pol Merkur Lekarski (2009) 0.75
[Evaluation of inflammatory and renal injury markers in youngest children with pyelonephritis]. Pol Merkur Lekarski (2008) 0.75
[The role of early-life metabolic programming in the pathogenesis of lifestyle diseases]. Dev Period Med (2015) 0.75
High-sensitivity C-reactive protein and mean platelet volume in paediatric hypertension. Pediatr Nephrol (2010) 0.75
Serum and urine fibronectin levels in children with vesicoureteral reflux. Pediatr Nephrol (2007) 0.75
Spontaneous urinary calcium oxalate crystallization in hypercalciuric children. Pediatr Nephrol (2009) 0.75
Vitamin D status in Poland. Pol Arch Med Wewn (2016) 0.75
[Bone mineral density in children and adolescents with idiopathic chronic musculoskeletal pain syndromes]. Pol Merkur Lekarski (2006) 0.75
[Assessment of transforming growth factor-beta1 in serum of children with idiopathic nephrotic syndrome depending on the way of treatment]. Pol Merkur Lekarski (2003) 0.75
Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A. Acta Paediatr (2006) 0.75
[Role of matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) in nephrology]. Przegl Lek (2009) 0.75
Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor. Eur J Pediatr (2006) 0.75
[Osteogenesis imperfecta as an interdisciplinary medical problem]. Chir Narzadow Ruchu Ortop Pol (2004) 0.75
[Reference values of 24-hour ambulatory blood pressure in healthy children by height]. Pol Merkur Lekarski (2004) 0.75
[Vertebral compression fractures--the first manifestations of acute lymphoblastic leukemia of childhood]. Med Wieku Rozwoj (2005) 0.75
[The evaluation of urinary tract dysfunction in children with monosymptomatic primary nocturnal enuresis]. Pol Merkur Lekarski (2008) 0.75
[Leptin, body composition and bone mineralization in children after treatment for Wilms tumor]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw (2004) 0.75
Increased circulating inflammatory markers may indicate that formula-fed children are at risk of atherosclerosis. Acta Paediatr (2014) 0.75
[Relationship between bone mineral content and growth disorders in children with juvenile idiopathic arthritis]. Pol Merkur Lekarski (2008) 0.75
[The concentration of plasma anion oxalate in children treatment antibiotics beta lactame]. Pol Merkur Lekarski (2006) 0.75
[The effect of cyclosporine A in steroid-dependent nephrotic syndrome in children]. Pol Merkur Lekarski (2005) 0.75
[Analysis of vesicoureteral reflux (VUR) course in children]. Pol Merkur Lekarski (2008) 0.75
[Effect of anticancer treatment on leptin level, fat body mass (FM) and lean body mass (LBM)]. Med Wieku Rozwoj (2005) 0.75
[Assessment of 24-hour blood pressure function of the single kidney in children with renal agenesis]. Pol Merkur Lekarski (2005) 0.75
[Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux]. Pol Merkur Lekarski (2010) 0.75
[Bone mineral density and markers of bone turnover in patients treated for malignant disease in childhood]. Med Wieku Rozwoj (2005) 0.75